RayKnowChina Research Map
Shortlist0

RecruitingStomach cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

Disitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Cancer With HER2 Overexpression

An open trial on stomach cancer, registered on ClinicalTrials.gov. Led by Tianjin Medical University Cancer Institute & Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorTianjin Medical University Cancer Institute & Hospital天津医科大学肿瘤医院TianjinHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06560528, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 8

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (8 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. 3) Gastric cancer or adenocarcinoma of gastroesophageal junction confirmed by histology and/or cytology;

    Inclusion criterion 3

  3. 4) Clinical stage Ⅱ, Ⅲ (cT2-4a ,N+ or -, M0, AJCC 8th);

    Inclusion criterion 4

  4. 5) Have not received systematic treatment;

    Inclusion criterion 5

    The patient has received possible curative treatment and there is no evidence of the disease within 5 years;

    Exclusion criterion 2

    3) Have received allogeneic stem cells or solid organ transplantation in the past;

    Exclusion criterion 5

    4) Patients who have received other anti-tumor systemic therapy in the past (including traditional Chinese medicine with anti-tumor indications), and have been less than 4 weeks from the completion of treatment to the administration of this study, or the adverse events caused by previous treatment have not recovered to ≤ CTCAE level 1 (except hair loss and pigmentation);

    Exclusion criterion 6

  5. 9) ECOG 0-1;

    Inclusion criterion 9

  6. 7) At least one assessable lesion (RECIST 1.1 );

    Inclusion criterion 7

  7. 1) Have a history of malignant tumors other than gastric cancer, except for the following two cases:

    Exclusion criterion 1

    6) Active or previously recorded autoimmune diseases or inflammatory diseases (including but not limited to: autoimmune hepatitis, interstitial pneumonia, inflammatory bowel disease, systemic lupus erythematosus, vasculitis, uveitis, hypophysitis, hyperthyroidism or hypothyroidism, asthma requiring bronchodilators, etc.), vitiligo or asthma that has completely alleviated in childhood, Those who do not need any intervention after adulthood can be included;

    Exclusion criterion 8

  8. 15) Pregnant or lactating women, and women or men with fertility who are unwilling or unable to take effective contraceptive measures;

    Exclusion criterion 20

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: blood tests: counts, liver and kidney function.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06560528, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • 1) Volunteer to take part in the study ;
  • 2) Age 18\~75 (including 75), male or female;
  • 3) Gastric cancer or adenocarcinoma of gastroesophageal junction confirmed by histology and/or cytology;
  • 4) Clinical stage Ⅱ, Ⅲ (cT2-4a ,N+ or -, M0, AJCC 8th);
  • 5) Have not received systematic treatment;
  • 6) The HER2 immunohistochemistry (IHC) test result is IHC 3+or 2+, and the previous test results of the subject (confirmed by the investigator) are acceptable;
  • 7) At least one assessable lesion (RECIST 1.1 );
  • 8) Expected survival time ≥ 6 months;
  • 9) ECOG 0-1;
  • 10) Major organs are functioning normally;

Exclusion Criteria:

  • 1) Have a history of malignant tumors other than gastric cancer, except for the following two cases:
  • The patient has received possible curative treatment and there is no evidence of the disease within 5 years;
  • The resected skin basal cell carcinoma, skin squamous cell carcinoma, superficial bladder cancer, cervical carcinoma in situ and other carcinoma in situ were successfully received;
  • 2) Suffering from diseases that affect the absorption, distribution, metabolism or clearance of the study drug (such as severe vomiting, chronic diarrhea, intestinal obstruction, absorption disorder, etc.);
  • 3) Have received allogeneic stem cells or solid organ transplantation in the past;
  • 4) Patients who have received other anti-tumor systemic therapy in the past (including traditional Chinese medicine with anti-tumor indications), and have been less than 4 weeks from the completion of treatment to the administration of this study, or the adverse events caused by previous treatment have not recovered to ≤ CTCAE level 1 (except hair loss and pigmentation);
  • 5) Previous or current congenital or acquired immunodeficiency disease;
  • 6) Active or previously recorded autoimmune diseases or inflammatory diseases (including but not limited to: autoimmune hepatitis, interstitial pneumonia, inflammatory bowel disease, systemic lupus erythematosus, vasculitis, uveitis, hypophysitis, hyperthyroidism or hypothyroidism, asthma requiring bronchodilators, etc.), vitiligo or asthma that has completely alleviated in childhood, Those who do not need any intervention after adulthood can be included;
  • 7) Systemic immunosuppressive drugs were used within 2 weeks before enrollment, or were expected to be required during the study, except for the following:
  • Corticosteroids for intranasal, inhalation, external or local injection (such as intra-articular injection);
  • The dose of prednisone or other equivalent systemic corticosteroids does not exceed 10 mg/day;
  • Preventive use of corticosteroids for hypersensitivity;
  • 8) Allergic to the study drug;
  • 9) Thrombosis or thromboembolism events occurred in the past 6 months, such as stroke and/or transient ischemic attack, deep vein thrombosis, pulmonary embolism, etc;
  • 10) Patients at risk for severe bleeding;
  • 11) Cardiovascular diseases with significant clinical significance;
  • 12) Other significant clinical and laboratory abnormalities, which the researchers think affect the safety evaluation;
  • 13) Serious infection in active period or poorly controlled clinically;
  • 14) Not recovered from the operation;
  • 15) Pregnant or lactating women, and women or men with fertility who are unwilling or unable to take effective contraceptive measures;
  • 16) Other situations that the investigator thinks are not suitable for inclusion.

Quoted from ClinicalTrials.gov, NCT06560528, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06560528, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06560528